Itraconazole-d5

Itraconazole-d5 is the deuterium labeled Itraconazole. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects[1][2][3].

Product Specifications

CAS Number

[1217510-38-7]

Product Name Alternative

R51211-d5

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Antibiotic; Autophagy; Cytochrome P450; Fungal; Hedgehog

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Autophagy; Metabolic Enzyme/Protease; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Purity

99.55

Solubility

DMF : ≥ 0.5mg/mL|DMSO : ≥ 0.5mg/mL

Smiles

ClC1=C(C=CC(Cl)=C1)[C@@]2(O[C@@H](COC3=CC=C(N4CCN(C5=CC=C(N(C=NN6C(C)C([2H])([2H])C([2H])([2H])[2H])C6=O)C=C5)CC4)C=C3)CO2)CN7C=NC=N7

Molecular Formula

C35H33D5Cl2N8O4

Molecular Weight

710.66

Precautions

H302, H315, H319, H335

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Kim, J., et al., Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell, 2010. 17 (4) : p. 388-99.|[3]Chong, C.R., et al., Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol, 2007. 2 (4) : p. 263-70.|[4]Pace JR, et al. Repurposing the Clinically Efficacious Antifungal Agent Itraconazole as an Anticancer Chemotherapeutic. J Med Chem. 2016 Apr 28;59 (8) :3635-49.